SITE013-0010

SITE013 (USA) › SITE013-0010

SITE013-0010

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE013 (USA) · Dr. Clarke
consented 2025-09-02

enrolled

AEs

3

Serious

0

Dropout signal

–

Adverse events

3

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-03-04 (study day 360); relationship: NOT RELATED

moderate assessed

Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-02-22 (study day 350); relationship: NOT RELATED

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-07-20 (study day 133); relationship: not assessed

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.